Intas Pharmaceuticals Limited Cisplatin Export Data — India (DGFT 2022–2026)

Name: Intas Pharmaceuticals Limited Cisplatin Export Records India — #3 Exporter, 73 Shipments, $1.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Cisplatin

India Pharmaceutical Trade Intelligence

$12.8M233 Suppliers130 CountriesHS 30049047

ExportsIndia → TAIWAN12.4%India → HUNGARY10.7%

ImportsGERMANY → India$9.5K UNITED STATES → India$2.3K

#1 Supplier: FRESENIUS KABI

Intas Pharmaceuticals Limited — Cisplatin Exporter #3 | $1.5M Trade Value | TransData Nexus | TransData Nexus

Intas Pharmaceuticals Limited — Cisplatin Exporter Profile

Indian Pharmaceutical Exporter · #3 for Cisplatin · $1.5M export value · DGFT Verified

Intas Pharmaceuticals Limited is the #3 Indian exporter of Cisplatin with $1.5M in export value and 73 verified shipments. Intas Pharmaceuticals Limited holds a 11.3% market share in Cisplatin exports across 13 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.

Intas Pharmaceuticals Limited — Cisplatin Export Profile: Buyers & Destinations

Intas Pharmaceuticals Limited Cisplatin export treemap — buyers and destination countries | TransData Nexus

Where Does Intas Pharmaceuticals Limited Export Cisplatin?

Country	Value	Shipments	Share
BRAZIL	$237.5K	23	16.8%
CANADA	$180.0K	5	12.7%
NETHERLANDS	$157.6K	9	11.1%
AUSTRALIA	$150.0K	3	10.6%
POLAND	$133.3K	5	9.4%

Who Are the Top Buyers of Cisplatin from Intas Pharmaceuticals Limited?

Buyer	Country	Value	Orders
XXCORXXHEAXXHCAXX INXX	CANADA	$200.0K	4
ACCORD FARMACUTICA LTDA.	BRAZIL	$129.0K	12
ACCORD HEALTHCARE B V	NETHERLANDS	$127.1K	6
ACCORD HEALTHCARE INC	CANADA	$114.8K	3
XXCORXXHEAXXHCAXX PTXXLIMITED	AUSTRALIA	$100.0K	2
ASIA UNITED BANK CORPORATION	PHILIPPINES	$89.3K	5
ACCORD HEALTHCARE POLSKA SP Z O O	POLAND	$86.6K	4
XXCORXXHEAXXHCAXX B XX	FRANCE	$74.7K	2
ACCORD FARMACUTICA LTDA	BRAZIL	$64.6K	6
XXCORXXHEAXXHCAXX LTXX	UNITED KINGDOM	$61.0K	9

Intas Pharmaceuticals Limited supplies Cisplatin to 29 buyers globally. The largest buyer is XXCORXXHEAXXHCAXX INXX (CANADA), followed by ACCORD FARMACUTICA LTDA. (BRAZIL) and ACCORD HEALTHCARE B V (NETHERLANDS). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Cisplatin Formulations Does Intas Pharmaceuticals Limited Export?

Product Description / Formulation	Value	Shipments
CISPLATIN INJ 1 MG/ML 100 ML	$152.6K	5
PHARMA DRUGS & MEDI CISPLATIN INJ BP 1MG	$137.4K	13
CISPLATIN INJECTION BP-1MG/ML(100MG/100M	$100.0K	2
CISPLATIN ACC INJ 100MG/100ML 1V(ACC-AUS	$100.0K	2
PHARMA DRUG&MED:PLATIN-Cisplatin 1mg/ml,	$53.2K	2
CISPLATIN 1MG/ML 100ML P1 ACO-FRANCE	$50.0K	2
CISPLATIN 1MG/ML 100ML P1 (ACO-FRANCE	$50.0K	1
CISPLATIN ACC INJ 100MG/100ML 1VACC-AUS	$50.0K	1
CISPLATIN INJECTION BP-1MG/ML100MG/100M	$50.0K	1
CISPLATIN 1MG/ML 100ML P1(ACO-POLAND	$46.7K	2

Intas Pharmaceuticals Limited exports 48 distinct Cisplatin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CISPLATIN INJ 1 MG/ML 100 ML with 5 shipments worth $152.6K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.

How Does Intas Pharmaceuticals Limited Compare to Nearest Cisplatin Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
1	FRESENIUS KABI ONCOLOGY LIMITED	$2.8M	60	8	$46.0K
2	VENUS REMEDIES LIMITED	$1.7M	121	22	$13.7K
3	INTAS PHARMACEUTICALS LIMITED ★	$1.5M	73	13	$19.9K
5	MYLAN LABORATORIES LIMITED	$775.1K	18	1	$43.1K
6	GLAND PHARMA LIMITED	$530.1K	11	1	$48.2K

Intas Pharmaceuticals Limited ranks #3 among 233 Indian Cisplatin exporters. Average shipment value of $19.9K compared to the market average of $41.2K. The closest competitors by value are FRESENIUS KABI ONCOLOGY LIMITED and VENUS REMEDIES LIMITED.

Which Indian Ports Ship Cisplatin Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	300	17.6%
SAHAR AIR	281	16.5%
DELHI AIR CARGO ACC (INDEL4)	260	15.3%
DELHI AIR	237	13.9%
Bombay Air	104	6.1%
Delhi Air	53	3.1%
Delhi Air Cargo	37	2.2%
HYDERABAD ACC (INHYD4)	35	2.1%

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Cisplatin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)

Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Cisplatin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 88 individual customs records matching Intas Pharmaceuticals Limited exporting Cisplatin, covering 48 formulations to 14 countries via 29 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 130+ countries, 584+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Cisplatin

Cisplatin

Intas Pharmaceuticals Limited — Cisplatin Exporter Profile

Intas Pharmaceuticals Limited — Cisplatin Export Profile: Buyers & Destinations

Where Does Intas Pharmaceuticals Limited Export Cisplatin?

Who Are the Top Buyers of Cisplatin from Intas Pharmaceuticals Limited?

What Is India's Total Cisplatin Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?

What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Cisplatin Exports?

How Does Intas Pharmaceuticals Limited Compare to Other Indian Cisplatin Exporters?

What Cisplatin Formulations Does Intas Pharmaceuticals Limited Export?

Regulatory Requirements: Exporting Cisplatin to Key Markets

Brazil — ANVISA

Canada — HC

How Does Intas Pharmaceuticals Limited Compare to Nearest Cisplatin Exporters?

Which Indian Ports Ship Cisplatin Exports?

Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Cisplatin Exports

Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards

About Intas Pharmaceuticals Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Cisplatin Export Data from Intas Pharmaceuticals Limited

Cisplatin Stats

Company Overview

Top Products by Intas Pharmaceuticals Limited

Related Analysis

Need Detailed Export Data?

Data Source